Recombinant interferon-alpha 2b and megestrol acetate in patients with advanced renal cell carcinoma.
Artigo
em Inglês
| IMSEAR
| ID: sea-45854
ABSTRACT
Fifteen patients with histologically proven metastatic or unresectable renal cell carcinoma were enrolled for a phase II trial of Interferon-alpha 2b (> or = 6 x 10(6) U/m2) plus megestrol acetate (160 mg/day). A response rate of 14.3 per cent was achieved in this study. We observed weight gain (median 3.2 kilogram; range 1.1 to 6.9) in 5 patients, and stable weight in 5 of the 14 patients who completed the protocol. Weight gain occurred regardless of extent of metastasis or response to interferon. Our data suggest a possible role for megestrol acetate in alleviating anorexia and weight loss in patients with renal cell carcinoma undergoing interferon treatment. Further clinical trials are clearly warranted.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Idoso
/
Feminino
/
Humanos
/
Masculino
/
Carcinoma de Células Renais
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Taxa de Sobrevida
/
Resultado do Tratamento
/
Interferon-alfa
/
Acetato de Megestrol
Tipo de estudo:
Guia de Prática Clínica
Idioma:
Inglês
Ano de publicação:
2000
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS